It most certainly IS an IND:
ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes
San Diego, CA — July 17, 2014 – ViaCyte, Inc., a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, today announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. The trial would evaluate the safety and efficacy of ViaCyte’s VC-01™ product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical Device Master File (called MAF) to the FDA in support of the Encaptra® drug delivery system, the device component of the VC-01 product candidate.
Don't sweat it. You made money. He lost money. That's why he's bitter.
I think you have a lot of burnt short sellers upset with their recent losses. It's not like posting here makes a difference but they need to vent somewhere. :)
Why is it always manipulation when your theories are wrong? It's not manipulation. You're just wrong . STEM is a winner and people are seeing that. AMD is a $30B market. That alone should be enough.
Nah Jason Kolbert works for Maxim and has a high target too. They didn't dilute on his PT raise. STEM just raised an extra $20MM from warrant executions at $1.80 during the last rally. You've just missed that very important piece of information. You keep crying dilution and the pps keeps rising. You need a better cry. :)
You're missing the $20MM worth of warrants that were executed during the rally at $1.80. They just did raise cash and you missed it!
The Beginning of the End Or the End of The Beginning?
This is about combining voice and gesture technology which is the next step in the evolution of mobile devices.
Nope. STEM did not raise its authorized shares at all last meeting. Nice try tho. CUR just DOUBLED it's AS and thus DOUBLED its potential dilution. Try reading the SEC filings first. You're getting dumber all by yourself.
Last STEM vote in April:
1. to elect the two Class II directors named in the accompanying proxy materials to serve until the 2017 Annual Meeting of Stockholders;
2. to consider and vote upon a proposal to ratify the selection of Grant Thornton LLP as independent public accountants for the company for the fiscal year ending December 31, 2014;
3. to conduct an advisory vote on executive compensation; and
4. to transact any and all other business that may properly come before the meeting.
STEM will be providing an update of its SCI program at a conference next week. More results. Probably will announce closing enrollment and starting Phase 2.
Yes. Although I calculate about $20MM on the exercise. That about doubles their cash and that's the end of dilution for the year at least. The dilution is already in. It's already been sold into the market. We're good to go!!
Read the Form 4 footnotes on that. It's a code F. That's taxes. If I give you 100 shares of a stock you still owe taxes on those shares even if you don't sell them. So what most do is have the company withhold or sell a small amount to cover the taxes. Pretty routine in any company where shares are awarded as salary. Non event.
ACTC has been promising that data for about a year now. In fact the guy who is in charge of that trial, Steven Schwartz was supposed to show up today and give a talk but he failed to show. Must have had a better gig.
There were 11MM warrants available for purchase from the last financing. STEM probably just raised another $20MM through the exercise of warrants that were priced at $1.80. They have more cash now than they did last week. Most People don't understand the financing. STEM's cash is better than it has ever been in its entire history.
Sentiment: Strong Buy
You've been saying this for years. They are not even close to $1.00. They aren't RSing. You missed the boat.
Give it a rest. You were wrong.
Sentiment: Strong Buy